Clinical Trial Update: Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

View source ↗

Summary

Post-marketing surveillance study to observe the safety and effectiveness of CRYSVITA (burosumab) in South Korean patients with FGF23-related hypophosphataemic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatemic Rickets
• Osteomalacia
• X-linked Hypophosphatemia

Drugs mentioned

• Crysvita (burosumab)

Snippet

Sponsor: Kyowa Kirin Korea Co., Ltd. | Conditions: FGF23-related Hypophosphataemic Rickets and Osteomalacia | Status: RECRUITING